Klaria Pharma Holding AB (KLAR) Stock Price & Analysis

7 Followers

KLAR Stock Chart & Stats

kr 0.50-kr 0.02(-3.08%)

At close: Nov 11 5:30 PM GMT+1

Day’s Range: SEK 0.49 - SEK 0.52
52-Week Range: SEK 0.45 - SEK 1.33
Previous Close: SEK 0.52
Volume: N/A
Average Volume (3M): 927.05K
Market Cap: SEK 127.91M
Enterprise Value: SEK 195.31M
Total Cash (Recent Filing): SEK 8.47M
Total Debt (Recent Filing): SEK 9.70M
Price to Earnings (P/E): ―
Beta: 1.78
Next Earnings: Nov 26, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Buccal Film Platform

Klaria has a defined technology platform rather than an undifferentiated drug-development approach. Applying buccal thin-film delivery across therapeutic areas could support multiple product programs and create reusable development expertise if candidates progress successfully.

Partnering-based Monetization

The business model can monetize development progress through licensing, upfront payments, milestones, and royalties rather than relying only on building a large commercial sales organization. This offers potential operating leverage if the platform attracts pharmaceutical partners.

Currently Moderate Debt

Debt is currently moderate in absolute terms and was reported at zero in 2025, which may reduce interest and refinancing pressure compared with a highly leveraged structure. This provides some balance-sheet support while the company advances its development programs, although equity remains stressed.

Bears Say

Minimal Revenue And Persistent Losses

The company has not yet demonstrated a sustainable commercial earnings base: TTM revenue is minimal while losses remain very large and margins are sharply negative. Persistent losses reduce internal funding capacity and leave future value dependent on successful product progress or external financing.

Ongoing Cash Burn

Continued negative operating and free cash flow shows that Klaria is not self-funding its operations or development activity. Ongoing cash consumption can constrain pipeline execution and increase reliance on financing, partnerships, or other capital sources over the coming quarters.

Negative Equity And Recapitalization Risk

Negative stockholders’ equity is a material structural weakness because it limits financial flexibility and signals that accumulated losses have eroded the capital base. Even with currently lower debt, the company may need recapitalization to sustain development and meet obligations.

KLAR FAQ

What was Klaria Pharma Holding AB’s price range in the past 12 months?

Klaria Pharma Holding AB lowest stock price was kr 0.45 and its highest was kr 1.33 in the past 12 months.

What is Klaria Pharma Holding AB’s market cap?

Klaria Pharma Holding AB’s market cap is kr 127.91M.

When is Klaria Pharma Holding AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Klaria Pharma Holding AB’s earnings last quarter?

Klaria Pharma Holding AB released its earnings results on Aug 31, 2026. The company reported -kr 0.052 earnings per share for the quarter.

Is Klaria Pharma Holding AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Klaria Pharma Holding AB pay dividends?

Klaria Pharma Holding AB does not currently pay dividends.

What is Klaria Pharma Holding AB’s EPS estimate?

Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Klaria Pharma Holding AB have?

Klaria Pharma Holding AB has 245,976,150 shares outstanding.

What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?

Klaria Pharma Holding AB reported an EPS of -kr 0.052 in its last earnings report. Following the earnings report the stock price went down -31.425%.

Which hedge fund is a major shareholder of Klaria Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:KLAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description